<SEC-DOCUMENT>0001178913-22-002166.txt : 20220525
<SEC-HEADER>0001178913-22-002166.hdr.sgml : 20220525
<ACCEPTANCE-DATETIME>20220525091704
ACCESSION NUMBER:		0001178913-22-002166
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20220525
FILED AS OF DATE:		20220525
DATE AS OF CHANGE:		20220525

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			RedHill Biopharma Ltd.
		CENTRAL INDEX KEY:			0001553846
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35773
		FILM NUMBER:		22959436

	BUSINESS ADDRESS:	
		STREET 1:		21 HA'ARBA'A STREET
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			64739
		BUSINESS PHONE:		972-3-541-3131

	MAIL ADDRESS:	
		STREET 1:		21 HA'ARBA'A STREET
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			64739
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>zk2227903.htm
<DESCRIPTION>6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K Global
         Document created using EDGARfilings PROfile 8.2.0.0
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"><br>
    <div>
      <div style="text-align: center; line-height: 1.25;"><font style="font-size: 14pt; font-family: 'Times New Roman',Times,serif; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;UNITED STATES&#160;</font><font style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;&#160;</font></div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">SECURITIES AND EXCHANGE COMMISSION</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Washington, D.C.&#160;20549</div>
      <div style="text-align: center; line-height: 1.25;">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">FORM 6-K</div>
      <div style="text-align: center; line-height: 1.25;">&#160;&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Report of Foreign Private Issuer</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Pursuant to Rule 13a-16 or 15d-16</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">of&#160;the Securities Exchange Act of 1934</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;</div>
      <div style="text-align: center; line-height: 1.25;">For the month of May 2022<br>
        Commission File No.:001-35773</div>
      <div style="text-align: center; line-height: 1.25;">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">REDHILL BIOPHARMA LTD.</div>
      <div style="text-align: center; line-height: 1.25;">(Translation of registrant&#8217;s name into English)</div>
      <div style="text-align: center; line-height: 1.25;">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">21 Ha'arba'a Street, Tel Aviv, 6473921, Israel</div>
      <div style="text-align: center; line-height: 1.25;">(Address of principal executive offices)</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 28.35pt; line-height: 1.25;">Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.&#160;&#160;</div>
      <div style="text-align: center; text-indent: 14.2pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: center; text-indent: 14.2pt; line-height: 1.25;">Form 20-F&#160;<font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9746;</font>&#160;Form 40-F&#160;<font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
      <div style="text-indent: 14.2pt; line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 28.35pt; line-height: 1.25;">Indicate by check mark if the Registrant is&#160;submitting&#160;the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____&#160;</div>
      <div style="text-indent: 28.35pt; line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 28.35pt; line-height: 1.25;">Indicate by check mark if the Registrant is&#160;submitting&#160;the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">Attached hereto and incorporated by reference herein is a press release issued by the Registrant entitled:&#160; <font style="font-style: italic;">"RedHill Presents New Talicia&#174; Data Analyses at DDW
          2022".</font></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <!--PROfilePageNumberReset%Num%2%%%-->
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25;">
        <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
          <div style="line-height: 1.25;">
            <div style="line-height: 1.25;"><a href="exhibit_99-1.htm">Exhibit 99.1</a> (excluding the posters therein) to this Report on Form 6-K is
              incorporated by reference into the Company's Registration Statements on Form S-8 filed with the Securities and Exchange Commission on May 2, 2013 (Registration No. 333-188286), on October 29, 2015 (Registration No. 333-207654), on July 25,
              2017 (Registration No. 333-219441), on May 23, 2018 (Registration No. 333-225122), on July 24, 2019 (File No. 333-232776), on March 25, 2021 (File No. 333-254692), on May 3, 2021 (File No. 333-255710) and on January 11, 2022 (File No.
              333-262099) and its Registration Statements on Form F-3 filed with the Securities and Exchange Commission on July 24, 2019 (File No. 333-232777), on March 30, 2021 (File No. 333-254828) and on July 29, 2021 (File No. 333-258259).</div>
          </div>
        </div>
      </div>
      <div style="line-height: 1.25">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">2</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">SIGNATURES</div>
      <div style="text-align: justify; text-indent: 28.35pt; line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">Pursuant to the requirements of&#160;the&#160;Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.&#160;</div>
      <div style="text-align: justify; margin-left: 220.65pt; line-height: 1.25;">&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z84bbaeede2264b49a53cd848ba40aa07">

          <tr>
            <td style="width: 49.66%; vertical-align: middle;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td colspan="2" style="vertical-align: middle;">
              <div style="line-height: 1.25;">REDHILL BIOPHARMA LTD.</div>
            </td>
            <td style="width: 20%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.66%; vertical-align: middle;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td colspan="2" style="vertical-align: middle;">
              <div style="line-height: 1.25;">(the "Registrant")</div>
            </td>
            <td style="width: 20%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.66%; vertical-align: middle;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 3%; vertical-align: middle;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 27%; vertical-align: middle;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 20%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.66%; vertical-align: middle;">
              <div style="line-height: 1.25;">Date: May 25, 2022</div>
            </td>
            <td style="width: 3%; vertical-align: middle;">
              <div style="line-height: 1.25;">By:</div>
            </td>
            <td style="width: 27%; vertical-align: middle; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25;">&#160;/s/ Dror Ben-Asher&#160;</div>
            </td>
            <td style="width: 20%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.66%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td colspan="2" style="vertical-align: middle;">
              <div style="line-height: 1.25;">Dror Ben-Asher&#160;</div>
            </td>
            <td style="width: 20%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.66%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td colspan="2" style="vertical-align: middle;">
              <div style="line-height: 1.25;">Chief Executive Officer</div>
            </td>
            <td style="width: 20%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    </div>
  </div>
  <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">3</font>
    <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; margin-left: auto; margin-right: auto;"></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit_99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K Global
         Document created using EDGARfilings PROfile 8.2.0.0
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div style="text-align: right;"><u> <font style="font-weight: bold;">Exhibit 99.1</font></u><br>
    </div>
    <div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;"><img width="150" height="89" src="image0.jpg"></div>
      <div style="line-height: 1.25;">
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="5" border="0" id="z94a215a9c6ff49b2891244e87e184518" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

            <tr>
              <td style="width: 100%; border-width: 1px; border-style: solid; border-color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 18pt; font-style: normal; font-variant: normal; text-transform: none;">
                <div style="line-height: 1.25;">
                  <div style="text-align: center; line-height: 1.25;">Press Release</div>
                </div>
              </td>
            </tr>

        </table>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;"><u>RedHill Presents New Talicia</u><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;"><u>&#174;</u></sup><u> Data Analyses at DDW 2022</u></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; margin-left: 18pt; line-height: 1.25; font-style: italic;">Talicia&#8217;s efficacy and safety profile evaluated in patients with H. pylori infection and diabetes </div>
      <div style="text-align: center; margin-left: 18pt; line-height: 1.25; font-style: italic;">mellitus, a large and challenging patient population associated with sub-optimal outcomes with </div>
      <div style="text-align: center; margin-left: 18pt; line-height: 1.25; font-style: italic;">clarithromycin-based H. pylori eradication therapy</div>
      <div style="text-align: center; margin-left: 18pt; line-height: 1.25; font-style: italic;">--</div>
      <div style="text-align: center; margin-left: 18pt; line-height: 1.25; font-style: italic;">Physiologically based pharmacokinetic modeling study of Talicia evaluated intragastric </div>
      <div style="text-align: center; margin-left: 18pt; line-height: 1.25; font-style: italic;">antibiotic exposure, which is critical for successful H. pylori eradication, by comparing low-dose </div>
      <div style="text-align: center; margin-left: 18pt; line-height: 1.25; font-style: italic;">rifabutin 50 mg every 8 hours to the generic formulation of rifabutin 150 mg once a day</div>
      <div style="text-align: center; margin-left: 18pt; line-height: 1.25; font-style: italic;">--</div>
      <div style="text-align: center; margin-left: 18pt; line-height: 1.25; font-style: italic;">Talicia, the leading FDA-approved brand for H. pylori treatment, is intended for empiric first-line </div>
      <div style="text-align: center; margin-left: 18pt; line-height: 1.25; font-style: italic;">eradication of H. pylori, a bacterial infection that affects approximately 35% of the U.S. </div>
      <div style="text-align: center; margin-left: 18pt; line-height: 1.25; font-style: italic;">adult population, representing significant unmet need</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;"><font style="font-weight: bold;">RALEIGH, N.C. and TEL AVIV, Israel, May 25, 2022, </font><u>RedHill Biopharma Ltd.</u> (Nasdaq: <u>RDHL</u>) (&#8220;RedHill&#8221; or the &#8220;Company&#8221;), a specialty
        biopharmaceutical company, announced the presentation of two new data analyses from the Talicia<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>&#160;<font style="font-style: italic;">H. pylori</font> eradication clinical trials program at Digestive Diseases Week (DDW) 2022.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">The first analysis evaluated the maintenance of Talicia&#8217;s efficacy and safety in the treatment of patients with <font style="font-style: italic;">H. pylori</font> infection and diabetes mellitus
        (DM). DM is associated with higher rates of <font style="font-style: italic;">H. pylori</font> infection and higher rates of treatment failure with clarithromycin-based therapies. Furthermore, clarithromycin interacts with some common diabetes
        medications potentially leading to hypoglycemia<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1</sup>.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">The second analysis, a physiologically based pharmacokinetic (PBPK) study, used modeling to compare Talicia&#8217;s low-dose rifabutin formulation&#8217;s (rifabutin 50 mg every 8 hours) sustained intragastric
        antibiotic exposure, a critical component of successful <font style="font-style: italic;">H. pylori</font> eradication, to exposure rates seen with the generic formulation of rifabutin (150 mg taken once daily (QD)).</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <!--PROfilePageNumberReset%Num%2%%%-->
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zaa671f5d36ae4e4d99a7eac16c94ff22">

          <tr>
            <td style="width: 85%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; text-align: justify;"><font style="font-weight: bold;">Poster one (poster number: Tu1078)</font>: <u>Low-Dose Rifabutin Triple Therapy (Talicia) Maintains High </u><font style="font-style: italic;"><u>Helicobacter pylori</u></font><u> Eradication Rates and Shows Favorable Safety and Efficacy in Subjects with Diabetes Mellitus</u>.</div>
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;"> <br>
                </font></div>
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; text-align: justify;"><font style="font-weight: bold;">Presenting Author</font>: Dr. Colin W. Howden, MD, Professor Emeritus, University of Tennessee Health Science
                Center</div>
            </td>
            <td style="width: 15%; vertical-align: middle;">
              <div style="text-align: right; line-height: 1.25; margin-left: 9pt;"><img width="123" height="124" src="image1.jpg"></div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">This supplemental analysis of the pooled modified intent-to-treat (mITT) population (n=293) from two Phase 3 clinical trials (ERADICATE Hp, ERADICATE Hp2) assessed the safety and efficacy of
        Talicia in patients with DM. <font style="font-style: italic;">H. pylori</font> isolates from treatment-na&#239;ve patients from study 2 were also tested for antibiotic resistance according to the presence of DM. The 293 patient-analyzable mITT
        population who received Talicia had pooled eradication rates of 91.7% (n=44) and 84.1% (n=206) in patients with and without DM, respectively (p=0.17).&#160;Moreover, no resistance was seen to rifabutin in patients with or without DM. Resistance rates
        were 4% v 7% for amoxicillin, 45% v 43% for metronidazole, and 21% v 17% resistance to clarithromycin in patients with and without DM, respectively.&#160;With the exception of an observed higher rate of diarrhea in patients without diabetes versus those
        with (13.8% vs 6%), the presence of diabetes did not alter the safety or tolerability of Talicia, and generally matched the safety profile of the total patient population. &#160;</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: justify; line-height: 1.25;">
          <div style="line-height: 1.25;">
            <div style="line-height: 1.25;">&#8220;More than 37 million Americans have diabetes, which presents significant issues in the treatment of <font style="font-style: italic;">H. pylori</font> infection. Firstly, we know that the risk of treatment failure with clarithromycin-based therapies is significantly higher in patients with diabetes<sup style="font-family: Calibri, sans-serif; vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup>, and secondly, the use of clarithromycin in diabetic patients can impair the management of their diabetes due to drug-drug interactions,&#8221; <font style="font-weight: bold;">said Dr. Barry Johns, MD, from The Jones Center for Diabetes and Endocrine Wellness, Macon, GA</font>. &#8220;Consequently, it is vital that we know which therapies are most appropriate for first-line
              <font style="font-style: italic;">H. pylori</font> eradication treatment. Since Talicia maintains high eradication rates and is well tolerated regardless of a patient&#8217;s diabetes,
              it represents a rational empiric first-line choice for the treatment of <font style="font-style: italic;">H. pylori</font> infection.&#8221;</div>
            <div style="line-height: 1.25">&#160;</div>
          </div>
        </div>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zf5396404b7df47b5a689ac248bc00194">

          <tr>
            <td style="width: 85%; vertical-align: top;">
              <div style="line-height: 1.25;">
                <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; text-align: justify;"><font style="font-weight: bold;">Poster two (poster number: Tu1077)</font>: <u>Low-Dose Rifabutin Triple Therapy Demonstrates High </u><font style="font-style: italic;"><u>Helicobacter pylori</u></font><u> Eradication Rates: Physiologically-Based Pharmacokinetic (PBPK) Modeling Supports Favorable Intragastric Rifabutin Concentrations for 50 mg Q8H Dosing vs. 150 mg QD&#160;</u></div>
                <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
              </div>
              <div style="line-height: 1.25;">
                <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Presenting Author</font>: Dr. Colin W. Howden, MD, Professor Emeritus, University of Tennessee Health Science Center.</div>
              </div>
            </td>
            <td style="width: 15%; vertical-align: middle;">
              <div style="text-align: right; line-height: 1.25; margin-left: 9pt;"><img width="133" height="132" src="image2.jpg"></div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;">
        <div style="text-align: justify; line-height: 1.25;">&#160;</div>
        <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">2</font></div>
          <div id="DSPFPageBreak" style="page-break-after: always;">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
      </div>
      <div style="text-align: justify; line-height: 1.25;">Sufficient intragastric antibiotic exposure is critical for eradication of <font style="font-style: italic;">H. pylori</font>. Consequently, understanding the influence of antibiotic dosing on
        intragastric exposure is imperative. This study used PBPK modeling to compare intragastric rifabutin concentrations with Talicia (low-dose rifabutin 50 mg) administered every 8 hours (Q8H) vs. rifabutin 150 mg (the generically available dose)
        administered once daily (QD). Intragastric rifabutin concentration time above the mean inhibitory concentration (MIC<sub style="vertical-align: bottom; line-height: 1; font-size: smaller;">90</sub> = 0.008 mcg/mL) was calculated over a 24-hour period for each regimen. Low-dose rifabutin 50 mg Q8H, as in Talicia,
        maintained intragastric rifabutin concentrations at or above the MIC<sub style="vertical-align: bottom; line-height: 1; font-size: smaller;">90</sub> for approximately three times longer than rifabutin 150 mg QD. When taken with food (as indicated in the prescribing information), low-dose rifabutin 50 mg Q8H, as in
        Talicia, provided intragastric concentrations at or above the MIC<sub style="vertical-align: bottom; line-height: 1; font-size: smaller;">90</sub> for about 93% of the day, compared to 35% of the day when dosed as 150 mg QD. &#160;</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">
        <div style="line-height: 1.25;">&#8220;Maintaining high intragastric antibiotic concentrations is necessary for successful <font style="font-style: italic;">H. pylori</font> eradication. Dosing rifabutin at 150 mg QD does not replicate the sustained intragastric concentrations predicted with low-dose rifabutin at 50 mg Q8H. The differences in
          intragastric exposure seen in this study may potentially explain the lower and less consistent eradication rates seen with generic rifabutin (about 70% eradication) than seen in the Talicia clinical trial program (about 84-90% eradication),&#8221; <font style="font-weight: bold;">said Dr. Colin W. Howden, MD, Professor Emeritus, University of Tennessee Health Science Center</font>. &#8220;Given the need to aim for the most effective
          empiric first-line eradication therapy, it is important to utilize a therapy with the highest likelihood of <font style="font-style: italic;">H. pylori</font> eradication success,
          such as Talicia.&#8221;</div>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">&#8220;These important new data enhance the body of evidence supporting the use of Talicia as a first line therapy for <font style="font-style: italic;">H. pylori</font>,&#8221; <font style="font-weight: bold;">said Dr. June Almenoff, MD, Ph.D., RedHill&#8217;s Chief Medical Officer</font>. &#8220;Talicia consistently shows its ability to maintain high <font style="font-style: italic;">H. pylori</font> eradication rates, even in challenging patient
        populations, with zero to minimal resistance. This work also demonstrates Talicia&#8217;s sustained intragastric exposure, providing optimized conditions for eradication of <font style="font-style: italic;">H. pylori</font> at the first treatment
        attempt.&#8221;</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: justify; line-height: 1.25;"><font style="font-weight: bold;">About&#160;</font><font style="font-weight: bold; font-style: italic;">H. pylori</font><font style="font-weight: bold;"> infection</font><br>
          <font style="font-style: italic;">H. pylori</font> is a bacterial infection that affects approximately 35%<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3</sup> of the U.S. population, with an estimated two million patients treated annually<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">4</sup>. Worldwide, more than 50% of the
          population has<br>
          <font style="font-style: italic;">H. pylori </font>infection, which is classified by the WHO as a Group 1 carcinogen. It remains the strongest known risk factor for gastric cancer<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">5</sup><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#160;</sup>and a major risk factor for peptic ulcer
          disease<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">6</sup>&#160;and gastric mucosa-associated lymphoid tissue (MALT) lymphoma<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">7</sup>. More than 27,000 Americans are diagnosed with gastric cancer annually<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">8</sup>. Eradication of&#160;<font style="font-style: italic;">H. pylori</font>&#160;is
          becoming increasingly difficult, with current therapies failing in approximately 25-40% of patients who remain&#160;<font style="font-style: italic;">H. pylori</font>-positive due to high resistance of&#160;<font style="font-style: italic;">H. pylori</font>&#160;to


          antibiotics &#8211; especially clarithromycin &#8211; which is still commonly used in standard combination therapies<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">9</sup>.</div>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;"><font style="font-weight: bold;">About Talicia</font><sup style="font-weight: bold; vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup><br>
        Talicia<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> is the only low-dose rifabutin-based therapy approved for the treatment of <font style="font-style: italic;">H. pylori</font> infection and is designed to address the high resistance of <font style="font-style: italic;">H.
          pylori</font> bacteria seen with other antibiotics. The high rates of <font style="font-style: italic;">H. pylori </font>resistance to clarithromycin have led to significant rates of treatment failure with clarithromycin-based therapies and are
        a strong public health concern, as highlighted by the ACG, FDA and the World Health Organization (WHO) in recent years.</div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">3</font></div>
          <div id="DSPFPageBreak" style="page-break-after: always;">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; line-height: 1.25;">Talicia<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> is a novel, fixed-dose, all-in-one oral capsule combination of two antibiotics (amoxicillin and rifabutin) and a proton pump inhibitor (PPI) (omeprazole). In November 2019,
          Talicia<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> was approved by the U.S. FDA for the treatment of <font style="font-style: italic;">H. pylori</font> infection in adults. In the pivotal Phase 3 study, Talicia<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174; </sup>demonstrated 84% eradication of <font style="font-style: italic;">H. pylori</font> infection in the intent-to-treat (ITT) group vs. 58% in the active comparator arm (p&lt;0.0001). Minimal to zero resistance to rifabutin, a key component of Talicia&#174;, was detected in RedHill&#8217;s
          pivotal Phase 3 study. Further, in an analysis of data from this study, it was observed that subjects who were confirmed adherent<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">10</sup> to their therapy had response rates of 90.3% in the Talicia<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> arm vs. 64.7% in the active
          comparator arm<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">11</sup>.<br>
          <br>
          Talicia<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> is eligible for a total of eight years of U.S. market exclusivity under its Qualified Infectious Disease Product (QIDP) designation and is also covered by U.S. patents which extend patent protection until 2034 with additional
          patents and applications pending and granted in various territories worldwide.</div>
        <div style="line-height: 1.25">&#160;</div>
      </div>
      <div style="text-align: justify; margin-right: 0.1pt; margin-left: 0.1pt; line-height: 1.25; font-weight: bold;">About RedHill Biopharma</div>
      <div style="text-align: justify; margin-right: 0.1pt; margin-left: 0.1pt; line-height: 1.25;">RedHill Biopharma Ltd. (Nasdaq: <u>RDHL</u>) is a specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases.
        RedHill promotes the gastrointestinal drugs, <font style="font-weight: bold;">Movantik</font><sup style="font-weight: bold; vertical-align: text-top; line-height: 1; font-size: smaller;">&#174; </sup>for opioid-induced constipation in adults<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">12</sup>, <font style="font-weight: bold;">Talicia</font><sup style="font-weight: bold; vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup><font style="font-weight: bold;">&#160;</font>for the treatment of <font style="font-style: italic;">Helicobacter pylori (H. pylori)</font> infection in adults<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">13</sup>, and <font style="font-weight: bold;">Aemcolo</font><sup style="font-weight: bold; vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> for the treatment of travelers&#8217; diarrhea in adults<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">14</sup>. RedHill&#8217;s key clinical late-stage development programs include: (i) <font style="font-weight: bold;">RHB-204</font>,<font style="font-weight: bold;">&#160;</font>with an ongoing Phase 3 study for pulmonary nontuberculous mycobacteria (NTM) disease; (ii) <font style="font-weight: bold;">opaganib (ABC294640)</font>, a first<font style="font-weight: bold;">-</font>in<font style="font-weight: bold;">-</font>class oral SK2 selective inhibitor targeting multiple indications with a Phase 2/3 program for hospitalized COVID-19 and Phase 2 studies for prostate cancer and cholangiocarcinoma ongoing; (iii) <font style="font-weight: bold;">RHB-107


        </font>(<font style="font-weight: bold;">upamostat</font>), an oral serine protease inhibitor in a Phase 2/3 study as treatment for non-hospitalized symptomatic COVID-19, and targeting multiple other cancer and inflammatory gastrointestinal
        diseases; (iv) <font style="font-weight: bold;">RHB-104</font>, with positive results from a first Phase 3 study for Crohn's disease; (v) <font style="font-weight: bold;">RHB-102</font> , with positive results from a Phase 3 study for acute
        gastroenteritis and gastritis and positive results from a Phase 2 study for IBS-D; and (vi) <font style="font-weight: bold;">RHB</font>-<font style="font-weight: bold;">106</font>, an encapsulated bowel preparation. More information about the
        Company is available at <u>www.redhillbio.com</u>/ <u>twitter.com/RedHillBio</u>.</div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold;">TALICIA: INDICATION AND IMPORTANT SAFETY INFORMATION</div>
        <div style="text-align: justify; line-height: 1.25;"><br>
          Talicia is a three-drug combination of omeprazole, a proton pump inhibitor, amoxicillin, a penicillin-class antibacterial, and rifabutin, a rifamycin antibacterial--, indicated for the treatment of&#160;<font style="font-style: italic;">Helicobacter
            pylori&#160;</font>infection in adults.<br>
          <br>
          To reduce the development of drug-resistant bacteria and maintain the effectiveness of Talicia and other antibacterial drugs, Talicia should be used only to treat or prevent infections that are proven or strongly suspected to be caused by
          bacteria.&#160;</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">4</font></div>
          <div id="DSPFPageBreak" style="page-break-after: always;">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold;">IMPORTANT SAFETY INFORMATION</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: justify; line-height: 1.25;"> <br>
        </div>
        <div style="text-align: justify; line-height: 1.25;">Talicia contains omeprazole, a proton pump inhibitor (PPI), amoxicillin, a penicillin-class antibacterial and rifabutin, a rifamycin antibacterial. It is contraindicated in patients with known
          hypersensitivity to any of these medications, any other components of the formulation, any other beta-lactams or any other rifamycin.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; line-height: 1.25;">Talicia is contraindicated in patients receiving rilpivirine-containing products.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; line-height: 1.25;">Talicia is contraindicated in patients receiving delavirdine or voriconazole.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; line-height: 1.25;">Serious and occasionally fatal hypersensitivity reactions have been reported with omeprazole, amoxicillin and rifabutin.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; line-height: 1.25;">Severe cutaneous adverse reactions (SCAR) (e.g., Stevens-Johnson syndrome (SJS), Toxic epidermal necrolysis (TEN)) have been reported with rifabutin, amoxicillin, and omeprazole. Additionally,
          drug reaction with eosinophilia and systemic symptoms (DRESS) has been reported with rifabutin.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; line-height: 1.25;">Acute Tubulointerstitial Nephritis has been observed in patients taking PPIs and penicillins.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; line-height: 1.25;"><font style="font-style: italic;">Clostridioides difficile</font>-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents and may range from mild diarrhea to
          fatal colitis.</div>
        <div style="text-align: justify; line-height: 1.25;"><br>
          Talicia may cause fetal harm. Talicia is not recommended for use in pregnancy. Talicia may reduce the efficacy of hormonal contraceptives. An additional non-hormonal method of contraception is recommended when taking Talicia.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; line-height: 1.25;">Talicia should not be used in patients with hepatic impairment or severe renal impairment.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; line-height: 1.25;">Cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE) have been reported in patients taking PPIs. These events have occurred as both new onset and exacerbation of existing
          autoimmune disease.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; line-height: 1.25;">The most common adverse reactions (&#8805;1%) were diarrhea, headache, nausea, abdominal pain, chromaturia, rash, dyspepsia, oropharyngeal pain, vomiting, and vulvovaginal candidiasis.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; line-height: 1.25;">To report SUSPECTED ADVERSE REACTIONS, contact RedHill Biopharma INC. at 1-833-ADRHILL (1-833-237-4455) or FDA at 1-800-FDA-1088 or <u>www.fda.gov/medwatch</u>. &#160;</div>
        <div style="line-height: 1.25">&#160;</div>
      </div>
      <div style="text-align: justify; line-height: 1.25;">Full prescribing information for Talicia&#160;is available at&#160;<u>www.Talicia.com</u></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">5</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic;">This press release contains &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words
        &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;plans,&#8221; &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;projects,&#8221; &#8220;predicts,&#8221; &#8220;estimates,&#8221; &#8220;aims,&#8221; &#8220;believes,&#8221; &#8220;hopes,&#8221; &#8220;potential&#8221; or similar words. Forward-looking statements are based on certain assumptions and are subject to various
        known and unknown risks and uncertainties, many of which are beyond the Company&#8217;s control and cannot be predicted or quantified, and consequently, actual results may differ materially from those expressed or implied by such forward-looking
        statements. Such risks and uncertainties, including without limitation risks regarding the treatment effectiveness of Talicia and the risk that the Company will not succeed to expand Talicia&#8217;s reach to additional ex-U.S. territories; as well as
        other risk and uncertainties associated with (i) the initiation, timing, progress and results of the Company&#8217;s research, manufacturing, pre-clinical studies, clinical trials, and other therapeutic candidate development efforts, and the timing of
        the commercial launch of its commercial products and ones it may acquire or develop in the future; (ii) the Company&#8217;s ability to advance its therapeutic candidates into clinical trials or to successfully complete its pre-clinical studies or
        clinical trials; (iii) the extent and number and type of additional studies that the Company may be required to conduct and the Company&#8217;s receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings,
        approvals and feedback; (iv) the manufacturing, clinical development, commercialization, and market acceptance of the Company&#8217;s therapeutic candidates and Talicia<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>; (v) the Company&#8217;s ability to successfully commercialize and promote
        Talicia<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>, Aemcolo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174; </sup>and Movantik<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>; (vi) the Company&#8217;s ability to establish and maintain corporate collaborations; (vii) the Company&#8217;s ability to acquire products approved for marketing in the U.S. that achieve
        commercial success and build its own marketing and commercialization capabilities; (viii) the interpretation of the properties and characteristics of the Company&#8217;s therapeutic candidates and the results obtained with its therapeutic candidates in
        research, pre-clinical studies or clinical trials; (ix) the implementation of the Company&#8217;s business model, strategic plans for its business and therapeutic candidates; (x) the scope of protection the Company is able to establish and maintain for
        intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; (xi) parties from whom the Company licenses its intellectual property defaulting
        in their obligations to the Company; (xii) estimates of the Company&#8217;s expenses, future revenues, capital requirements and needs for additional financing; (xiii) the effect of patients suffering adverse experiences using investigative drugs under
        the Company&#8217;s Expanded Access Program; and (xiv) competition from other companies and technologies within the Company&#8217;s industry. More detailed information about the Company and the risk factors that may affect the realization of forward-looking
        statements is set forth in the Company&#8217;s filings with the Securities and Exchange Commission (SEC), including the Company&#8217;s Annual Report on Form 20-F filed with the SEC on March 17, 2022. All forward-looking statements included in this press
        release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement, whether as a result of new information, future events or otherwise unless required by law.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z24e0ba2e4df64c4aa0b2482a5038f31f">

            <tr>
              <td style="width: 58.99%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">
                <div style="line-height: 1.25; font-weight: bold;">Company contact:</div>
                <div style="line-height: 1.25;">Adi Frish</div>
                <div style="line-height: 1.25;">Chief Corporate &amp; Business Development Officer</div>
                <div style="line-height: 1.25;">RedHill Biopharma</div>
                <div style="line-height: 1.25;">+972-54-6543-112</div>
                <div style="line-height: 1.25;"><u>adi@redhillbio.com</u></div>
              </td>
              <td style="width: 41.01%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                <div style="line-height: 1.25; font-weight: bold;">Media contacts:</div>
                <div style="line-height: 1.25;"><font style="font-weight: bold;">U.S.&#160; / UK:</font>&#160;Amber Fennell, Consilium</div>
                <div style="line-height: 1.25;">+44 (0) 7739 658 783 &#160;</div>
                <div style="line-height: 1.25;"><u>fennell@consilium-comms.com</u></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <hr noshade="noshade" align="left" style="background-color: #000000; border: 0px; height: 1px; width: 2in; margin-left: 0pt; margin-right: auto; color: #000000;">
      <div style="line-height: 1.25;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1</sup> Kennedy KE, Teng C, Patek TM, Frei CR. Hypoglycemia Associated with Antibiotics Alone and in Combination with Sulfonylureas and Meglitinides: An Epidemiologic Surveillance Study of the FDA Adverse Event
        Reporting System (FAERS). Drug Saf. 2020 Apr;43(4):363-369. doi: 10.1007/s40264-019-00901-7. PMID: 31863282; PMCID: PMC7117991.</div>
      <div style="line-height: 1.25;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup> Chey WD, et al. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection [published correction appears in Am J Gastroenterol. 2018 Jul;113(7):1102]. Am J Gastroenterol. 2017;112(2):212-239.</div>
      <div style="line-height: 1.25;">Horikawa C, et al. High risk of failing eradication of Helicobacter pylori in patients with diabetes: a meta-analysis. Diabetes Res Clin Pract. 2014;106(1):81-87.</div>
      <div style="text-align: justify; line-height: 1.25;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3</sup> Hooi JKY et al. Global Prevalence of <font style="font-style: italic;">Helicobacter pylori</font> Infection: Systematic Review and Meta-Analysis. Gastroenterology 2017; 153:420-429.</div>
      <div style="text-align: justify; line-height: 1.25;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">4</sup> IQVIA Custom Study for RedHill Biopharma, 2019</div>
      <div style="text-align: justify; line-height: 1.25;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">5</sup> Lamb A et al. Role of the <font style="font-style: italic;">Helicobacter pylori</font>&#8208;Induced inflammatory response in the development of gastric cancer. J Cell Biochem
        2013;114.3:491-497.</div>
      <div style="text-align: justify; line-height: 1.25;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">6</sup> NIH &#8211; <font style="font-style: italic;">Helicobacter pylori</font> and Cancer, September 2013.</div>
      <div style="text-align: justify; line-height: 1.25;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">7</sup> Hu Q et al. Gastric mucosa-associated lymphoid tissue lymphoma and <font style="font-style: italic;">Helicobacter pylori</font> infection: a review of current diagnosis and
        management. Biomarker research 2016;4.1:15.</div>
      <div style="text-align: justify; line-height: 1.25;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">8</sup> National Cancer Institute, Surveillance, Epidemiology, and End Results Program (SEER).</div>
      <div style="text-align: justify; line-height: 1.25;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">9</sup> Malfertheiner P. et al. Management of&#160;<font style="font-style: italic;">Helicobacter pylori</font>&#160;infection - the Maastricht IV/ Florence Consensus Report, Gut 2012;61:646-664;
        O&#8217;Connor A. et al. Treatment of&#160;<font style="font-style: italic;">Helicobacter pylori&#160;</font>Infection 2015, Helicobacter 20 (S1) 54-61; Venerito M. et al. Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric
        primary treatment of&#160;<font style="font-style: italic;">Helicobacter pylori</font>&#160;infection. Digestion 2013;88(1):33-45.</div>
      <div style="text-align: justify; line-height: 1.25;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">10</sup> Defined as the PK population which included those subjects in the ITT population who had demonstrated presence of any component of investigational drug at visit 3 (approx. day 13) or
        had undetected levels drawn &gt;250 hours after the last dose.</div>
      <div style="text-align: justify; line-height: 1.25;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">11</sup> The pivotal Phase 3 study with Talicia<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> demonstrated 84% eradication of <font style="font-style: italic;">H. pylori</font> infection with Talicia<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> vs. 58% in
        the active comparator arm (ITT analysis, p&lt;0.0001).</div>
      <div style="line-height: 1.25;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">12</sup> Movantik&#174; (naloxegol) is indicated for opioid-induced constipation (OIC). Full prescribing information see: www.movantik.com.</div>
      <div style="line-height: 1.25;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">13</sup> Talicia<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> (omeprazole magnesium, amoxicillin and rifabutin) is indicated for the treatment of <font style="font-style: italic;">H. pylori </font>infection in adults. For full prescribing
        information see: www.Talicia.com.</div>
      <div style="line-height: 1.25;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">14</sup> Aemcolo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> (rifamycin) is indicated for the treatment of travelers&#8217; diarrhea caused by noninvasive strains of <font style="font-style: italic;">Escherichia coli</font> in adults. For full
        prescribing information see: www.aemcolo.com.</div>
    </div>
    <div> <br>
    </div>
  </div>
  <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">6</font>
    <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; margin-left: auto; margin-right: auto;"></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image0.jpg
<TEXT>
begin 644 image0.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #, 5@# 2(  A$! Q$!_\0
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M'RU8M!1115&(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%8/B?7?[(L3' 0;R480?W
M!_>/]*F4E%79=.G*I)1B<U\0?%,D2MH^G2LLG_+Q*AP5_P!D'U]?R]:\IN(W
ME8M(S.QZECDUT,T+.[.Y+,QR2>I-4I+?VKR:E1SE=GUF#A##P48G.2V@/:J;
MV[)TYKI)+?VJG);>U2I-'J0KF#16C+: ]JIO R=.:M23.F,TR*NBMO'?BBU1
M5BUNZVJ, .0^!_P(&N=HJTVM@J4J=16G%/U/2_"OQ7U2'5HXO$%P+BQD^5I!
M$JM$?[WR@9'K7ML<B2QK)&ZO&X#*RG((/0BOD>NDTOQ[XET;3X[&QU(I;QYV
M(T2/M]@6!./:MZ==QTEJ>'F&21K-3P]HOJME^!]+45\\0?%/Q;'<Q22ZDLT:
M,"T301@..X)"@\^U>[:'K-IK^D6^I6;9BF7)4]4;NI]P:Z858SV/G\;EE;!I
M2J6:?8T:***T//"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHI'=8T+L<*!DF@"M?WT>GVC3R<XX5>['TKS
M;4'FOKJ2XG;<[G\O8>U=)JMP]_/N.1&O"+Z5D26_M7#7FYNW0]3"P5-7>[,&
M2W]JJ26_M6_)![55DM_:N5Q/1C5.?DM_:JDEO[5T$EO[55DM_:H:.F%4YV2V
M]JJ26_M7126_M522W]J1U0K'-RV@/:J;P,GO7226WM5.2V]JI2L=<*YA45H2
MV@/:JCPLG;-6I)G3&:9%6MI/B?6M"ADATS4);:.1MS*N""?7D5DT52;6PYPC
M-<LU=>9[_P##'Q9-XBT::VOYO-U"T;YG;&70]#^'(_ >M=W7R7;7=S9R&2UN
M)8'(P6B<J<>F17;>$OB?J>A.8-2:74;)LG#OF1#[,>H]C773Q"LE(^9Q^1SE
M.56A]W^1[]17A-U\8=>DU9+BWAMX;-#_ ,>I7=O'^TW7/TQ7I&@?$;0-;L6F
MENX[">-<RPW,@7'N">&'Z^U:QK0D[(\G$95BJ$5.4;KRUMZG745P&K_%WP]8
M;DLA-J$HZ>6NQ/\ OIOZ UJ>$/'FF^+(O+3_ $:_49>V=LDCU4_Q#]15*I%N
MR9C/ 8F%/VLH-+^OF=714<T\-O&9)Y4B0=6=@H'XFEBECGB66&1)(W&5=&R"
M/4$59RV=KCZ**JQ:E8SWDMG%>6[W41Q)"L@+KWY'6@$F]BU17*^+/'ND^%HV
MBD;[3?D?+:QMR/=C_"/U]JRO!?Q-M/$,HL=26.SU!F_=X/[N7T )Z-['KV]*
MCVD>;EN=4<#B)4764?=._HHHJSD"BBB@ HHHH **** "BBB@ HHKP[QI\5/%
M&B^-]0T;34M'BAD5(E: L[953C@\G)H ]QHKY]_X6C\2?^@/_P"4Z2C_ (6C
M\2?^@/\ ^4Z2@#Z"HKY[?XN?$&S'G76E0K$.IEL9%7\\BNJ\*_''3]3N8[/7
M;4:=*Y"K<(VZ(G_:SROUY'KB@#UJLS4)#*/*7[@Z^]:#'<GRG((ZBJCPU$[M
M6+A9.YAO![56>#VK;DA]JK/#[5SN!UQJ&))![55D@]JW'@]JK20>U9.!O&H8
M4D'M522W]JWI(/:JLD'M63B=$:I@R6_M522W]JWY+?VJK);^U9N)T1JG/R6_
MM522W]JSM;U^^L?%L6F1"+R'>)3E,GYL9YKIY+?VHG3<4F^IK1Q49MI=#GI+
M?VJG+;>U5)=;O/\ A*3IN(O)\_R_N\X^M=%);^U$X2A:_4Z</C(U;\O30YN6
MT![53>%D[9KI)+;VJI);>U)2L>C"N85%7;FVVQNX'*@FL:PN);DR;P/E Z"M
MHQ<HN2Z!+&THU8TGO+8N44R5BD,C#JJDC\J@LIWN(V9\9!QP*:BW'F+GB81K
M1H/XI:EJI(9Y;:=)X)7BE0[D=&*LI]015.\F>"#>F,[@.?QI]O(TMNCMC)'.
M*.5\O,)8FG*N\/U2OY6+ES>75[)YEW<S3O\ WI9"Q_,UO>%O&^K>%9@+:3SK
M,G+VLI^0^X_NGW'XYKC;ZZDMW0)CD<Y%73UIVE&TNYFIT,3*>'<;\N_;Y'MN
ML_%S3CX8\[2MXU2;Y!#(O^H/=B>A'IZ_G7BS3S/<-<-*YF9MYD+'<6ZYSZU'
M11.I*>X\)@:.$35-;CG=Y'9Y&9G8Y9F.23302#D<$445!V'J7@[XL-I]I]B\
M0":XCC7]U<(-TG^ZV3S]?SKN_"_Q"TGQ3?S65NDMO.HW1I/@&5>^,$\CT_\
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M?PKX:AFEA7^U+R,27$A'S*#R$'H!W]\^U=O7CW_#0.F_] *[_P"_R_X4?\-
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MX!YP6W8^E 'H=%%% !7)^%/^1F\8?]A&/_T1'765R?A3_D9O&'_81C_]$1T
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MZOI]SK=BG$6HV"!IMO82Q=2?]I<Y^M=I10!R7_"P])8;8K'6IIO^>*:9-O\
MU4#]:JS6FO>-B(-1M9-%\/DYDMV<?:KL?W6V\1H>XSD_C7;T4 ,AACMX(X88
MUCBC4(B*,!0.  /2N4N427XK6L<BAD;0IE96&009H\@UUU<G-_R5JS_[ DW_
M *.CH JQVNN^"F:'3;-]9\/Y)CMD<"YLQ_=3=Q(GH,Y'3M5D?$/25&V:QUJ"
M;_GC)IDV[]%(_6NMHH XJYO_ !#XM0V6EV-WH>FR<3ZA>*$G9>XBCZ@G^\V,
M>F:ZG2M+M-%TNWTZPB$5M;IL11_,^I)Y)]35RB@#FO%%A=7FK>&9;>!Y$MM2
M\V9E'W$\MQD^V2*Z6BB@ HHHH YKPA875C+XB-U \0N-9FGAW?QQE4 8>W!_
M*J6H:7K/A[7[K7- MUOK6^PU_II<(Q<#'FQ$\;L=0>N/R[*B@#DA\0M,C&+S
M3M;LY>\4VFRD_FH(/YU'+XLUG5AY'AOP[>;VX^V:I&;>"/\ VMI^=_H *[&B
M@#@M1\#72>$=32"?^T?$%Y)%<S7,V$\]XW5P@[*N%( Z#-='HFN76JR21W.A
M:CIK1H"6N@FQCZ*58Y_(5M44 <WX$L;K3?"%M:WD#PSK-<,4?J T\C#\P0?Q
MKI*** .;UNQNKCQCX6NX8'>"UDN3/(.B!H2JY^IXKI*** "N;\86-U?0Z*+6
M!Y3#J]M-)M_A16^9C["NDHH **** .;\?6-UJ7@?5+.R@>>XEC4)&G5OG4_T
MK8U73;;6=*NM-O$W6]S&8W ZX/<>XZU<HH XBRU;Q!X4A73];TN[U6TA&R#4
M]/3S'=!T\V/.X,!U(SFK1^(>D$;8;+6IY?\ GE'IDV[]5 _6NMHH X>X@\1^
M-1]FN;:30=!?_7*[@W=TO]WCB-3WY)_.EO+.\\,>+(M3TW1)KW2FTU+$PV17
MS("CDKA6(RI#8Z]J[>B@"M8737MC#<O:SVK2+DPS@!T]B 2,_C15FB@ HHHH
M **** "BBB@ HHHH **** "BBB@ K%DT:9_&L&N"2/R(]/>T,?.XLTBMGTQA
M:VJ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
5HHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image1.jpg
<TEXT>
begin 644 image1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &$ 8$# 2(  A$! Q$!_\0
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MJ*90!]Y:3JUCKFG17^GW"3V\HRK(P/X''>KM>;_ [_DFUO\ ]=C_ .@K7I%
M!1110 4444 %%%% !1110 5F:[X@TSPWIQOM4N4@@!P"S 9/H,]:TZ\@_:'_
M .1(M/\ KY_I0!T'_"YO!7_03_\ 0?\ &C_A<W@H==2Q]0/\:^/ZDF_UGX#^
M5 'UY_PN7P8>$U!G;^ZH!/\ .C_A<W@K_H)_^@_XU\EZ9_Q_I_NO_P"@FJ=
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M=/!W_/[K7_@1'_\ &Z]&\*_\BAHG_7A!_P"BUK4EFBA4&614!. 6.* /)?\
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M-']UB[*1T]"/04 ?$*_?7ZU]XZ00=)M2/[@KCX?@YX'MIEGCT9=T9R,RR?\
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MN]2\ 7%M96TMQ,SKA(D+'[P["NL\*_\ (H:)_P!>$'_HM:UZ /A__A"/$_\
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MU<S\1?\ DF_B3_L'3_\ H!H ^)J^D_V<O^1<U'_KO_05\V5])_LY?\BYJ/\
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M#Q1#HS(;6&=3YKJQ8X )[^X% '%5:G_X\;3Z/_Z%7TF/V=_#F/\ C\N/R/\
M\53C^SWX?951KZX*)]T;3QZ_Q4 ?,2??%-KZ>'[/'AP'(O+C\C_\51_PSOX;
M_P"?RX_(_P#Q5 '(_LX?\A_4_P#KV/\ Z$E?1]<;X(^&^D>!GN)+!I))IQM9
MW)X'IC)]!794 ?%_Q0_Y*/KG_7W+_P"AM7))T;_=KZR\2?!3P_XDUNXU266:
M&:=B\@4D@L3DG[WO62/V>/#@Z7EQSUX/_P 50!\PU;G_ .09:?[TG]*^D_\
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MEO\ ]_5_QKR']H>_N[3PYIZ6]S+$KW(W!'(S\K]<5\Y?VI?_ //[<?\ ?PT
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M?;M%X&/]?+_\;J";X!>+M,C^W27.E2QP'S&6*:0L0.3@%!7U-535/^01>_\
M7!__ $$T ?"5ZACOKA&X996!_.NR^%OC"W\%>(IM3NX99;?RMDBQ %L9[9([
M^]<GJ_\ R&K_ /Z^)/\ T(U';_\ 'M=?[@_]"% 'TS_PT9X._P"?'6O^_$7_
M ,<I6_:*\'J<&QUK_OQ%_P#'*^7*DF_UGX#^5 'T/XE^.?A[Q!H-UI6FV6I+
M/<H5#7$2*HQSV<^GI7SI5S3/^/\ 3_=?_P!!-4Z /H/]FS_4:U_OK_(5[V2
M,GH*\$_9L_U&M?[Z_P A7O;_ '&^E 'F.M?'3POH.M7>F75MJ,LEO(8R]O$C
M*2"0>KCTK0\)?%[P[XRUC^S=/CO()MA8"Z15W<@8&&/K7R[XV!'CWQ%D$?\
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M7IM '!W?P>\&7EW+<RZ;B25R[;2 ,GD\8J+_ (4MX*' L) #U <<_7BO0:*
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M[3UX8%CW#YSU_NT ?<WA@D^$M&)ZFQ@_]%K7$_'4D?#:[ /5TS_WT*\]T/\
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M#=SH364=^#%YZW7F%#C(.W8,\CUJHW[-#;SM\4_+GC_0/_ME 'A0_P"0:_\
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M!=RQH,] '('\JZSX1V4.O^/+6SU-?M%L58M&_(/RF@#SO!]*M3_\>-I]'_\
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M+?#+5 .?N?\ H0KX[P?2O5OA?XNU[6/&MMI.HZE-=V5V&6:*8Y#  \5]#?\
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M_P!<A_6F0_\ +3_<-=9\185T;QWJEC8$PVT4S!$7H!DUS45Y<MOS,QPA(YH
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MD8$*&)SR2.. :^S*\Y^-W_)-;O\ ZZ#^34 ?*7]GG_GZM/\ O\*Z+2/ >O\
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M /Q=>1);S!LF)_\ OFD^S3GI"_\ WS0![(/VA?$YLVG^PZ9Q($QY3]P3_?\
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MS_Y_Q_WZ:NV\,_"[6?&>DQW6F.AMHBRB1\+N))[$CT- '%Z0/-UFRC<DJTZ
MC/49%?<D&D:=;P1PQV5N$C4*H\L'@5\YZ;\!]?T_48+V]N88[:W;SI&&#@+S
MV;VKT"7]H'PK',Z*LSJK$!@K<^_W: ,']HFRM;;1M-F@@CBD:X )1<9&UO3Z
M5\\;F_O'\Z]?^*GQ#TKQYIUK#9AX(;>4,TK@G)P>,8'J?RKRO[/9_P#/^/\
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M!!D7_EJ?7ZUZ>?V?O%+!1YD VC'WE_\ BJ6+X >*894E#P,48-MW*,X[?>H
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M_P"T8ZQZQI3-&L@-OC:V<?>?TKQ$7$6X?Z)%U]6_QH ^W_"__(I:+_UX0?\
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M:2:,6L+&WC();"Y.!T]Z (+'_C_@_P!\5][U\(65Q&;V$"UC'SCD$_XU]WT
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M,B#0-2!9@ 3:N!^>*^X** ,WP_!):^&M*MYE*RQ6<*.I[$( 16E110 4444
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M^^*^]Z /)OCSH>I:SX7M/[.LY;IHILLD2EFP?8<]J^=?^$-\3?\ 0OZG_P"
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M^A6+_P +F^'_ /T,4?\ X#3?_$4?\+F^'_\ T,4?_@--_P#$4 ;7_""^%_\
MH!V7_?H4?\(+X7_Z =E_WZ%'A[QSX;\5SR0:)J:W<D2[G41.N!Q_>4>HKH:
M/BCXB6T%GX^UFVMHDBACNI51$&  '( JU\*/^2H:#_U\C^1J+XF_\E'UW_K\
ME_\ 0VJ7X4?\E0T'_KY'\C0!]FUFZIH&DZWY?]I6$%SY>=AD0$KG&<?D*TJP
MO$7C/P]X4\G^W-22T\[/E@QN^[&,_=!]10!!_P (!X5_Z EG_P!^Q2#P!X5
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MMI7C^PA=R*2,[WXXKRG2=.OFUFQ46<Y)N(_^69_O"ON6>TMKH 7%O%*!T\Q
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MC;2?&MB]WI7G!8SAUF4!E/X$U\1U]&_LX?\ ((U7_KH* /<J*** /!OVD?\
MCQTG_KK_ $>OGFOI?X^:#JFN6NF)IEE+=,CY81XX&&_QKP[_ (5[XM_Z 5U^
M0_QH V+3XQ^,K*R@M(+]%A@C6-!LZ*HP._H*F_X7;XW_ .@BG_?!_P :P?\
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M,@?,V0<?H: ,7[8W_/&#_OT*ZC0O'_B#PK8*NDW0ACF8[H]OR\>@SCN:R?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
FHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image2.jpg
<TEXT>
begin 644 image2.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $? 2$# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#L/B-\7?\
MA M<@TW^R/MGFP"7?YVS'.,8P?2N._X:6_ZEK_R:_P#L:POVC/\ D>+#_KR'
M_H1K%^&_PI;X@Z9>WBZL++[-,(MI@W[LKG.<B@#M_P#AI;_J6O\ R:_^QH_X
M:6_ZEK_R:_\ L:;_ ,,T2?\ 0S)_X"'_ .*I/^&:)/\ H9D_\!#_ /%4 /\
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M&E 'I_Q]_P"293_]?$7_ *$*\9^!?_)4;+I_J9>H]J]F^/O_ "3*?_KXB_\
M0A7C/P+_ .2HV7_7&3^5 'TWXQT%_$_A+4=&CF$+W4119&&0IZBOGO6?@1JW
MAS1KO6)M6M9H[6,NT:QD$C&./SKZ.U_7+7PWH5WJ]Z)#;VL9=Q&,L?8"O&O%
M'QS\.>(O"^HZ19V.II<7<)C1I40*/J0Q/Z4 >%:-<1Z?KNGWJ/O:WN8Y0A7
M8JP.,_A7NM_^T5I5YIUS;1:'=K)-$T89I5P"1BO!-,M'O-6L[6%E:6:=(T'/
M+%@!V]:]+NOV?O%MC8R7C76EN(4,C1I,V[ &3U4#]: /+F2'><S-U_N?_7KV
M6W_9PUIXXWEUFT1B 601$X]NM>+LB[F_>+U]#_A7WRG^K7@C@<&@"#3K7[!I
MEI9[M_V>%(MV,9VJ!G]*\HUG]H'1](UJ\TTZ/>2M:S-$SB10"5.#Q7L%?.GB
M3X ^)M4\2ZCJ%KJ&E^1=7#S+YCR*P#$G!&T]/K0![UH&L0^(-!LM6MT9(;N(
M2*K]0#ZUY[XL^.&E>%/$=UHTNE75Q);D!Y%D51G&:[GPEHLOAWPGIFD3RI++
M:0"-G3HQ'<5\J_%]0?BCK674?O1U!_NB@#ZG\'^*+;QCX:M]:M8)((YBR^7)
MU4J2#SWZ5RGCGXPZ;X'UT:3<:;<74WE+(6C=5 !Z=:\Z^&_Q@T/P5X+M=&U*
MSOI9D=Y%>V12I5F/7<0<]:X3XG^*[/QMXK_MBQCE@MS"L:K./F.WN<9'ZT ?
M3_@+QO:>/=#FU.TM9;98K@V[)(03D*K9R/9A7CO[201M=T+=)M_T:3H,_P 0
MKJ?V<0!X$U+!!_XF;\C_ *Y1URO[28SKNA98+_HTG7_>% '+?"WXC6?P\_M)
MKBSFO4O=@'ED*5*9]?7=7=ZG?P?'^T&GZ4)-+N--<3-]H^=74@KV[UX 47R%
M_>+]X\X/M7H?PE\=:=X!U#4+S48+BXAN8UB'V9064@YZ,1QQZT =MI/A_P#X
M4,TWB'6+C^T1=@6L4-JNTY^\22WTJS?^+[+XXV,GA/3X)M,NP1<I+,0Z$*>0
M<8[&G>(-;LOCMIHT/PX9;.]LG%R1J";4=?NG!0MSSZ5=^%GPAUOP5XJ;5]3O
M+"2,0-$J6[NS$MCGE1Z4 +\._@O?^#O%L6L7>J03QQQLH2.,@DGZUV?Q:_Y)
M7X@_Z]Q_Z&M=I7%_%K/_  JOQ!C_ )]Q_P"AK0!\N?#G_DHN@_\ 7VE?9.LZ
MFFBZ'J&J2QM)'96TEPR*0"P12Q S]*^-?AU_R430?^OM:^N/'1Q\/O$G('_$
MKN?_ $4U 'F/_#26C_\ 0"O/^_R_X4?\-):/_P! *\_[_+_A7S=10!])#]I'
M1R0/["O.?^FR_P"%>SVEP+NR@N0I431K(%/49&<5\$1_ZU/]X5]WZ+_R =._
MZ]H__010!\4>+O\ D<=8_P"OR7_T(U]A> /^2>>'?^P=!_Z *^/?%W_(XZQ_
MU^2_^A&OL+P!_P D[\._]@Z#_P! % '1T444 ?,7[1G_ "/%A_UY#_T(UU_[
M-G_(M:W_ -?B_P#H%<A^T9_R/%CS_P N0_\ 0C77_LV?\BUK?_7XO_H% &)^
MTI_R%-"_ZXR?^A"O":^F_C9X"\1>,K_2I-#LEN$MXG60M,B8)/'WB*\J_P"%
M&?$#_H#Q?^!D7_Q5 'G->O\ [.8_XK^].,XTY_P^=*Q?^%&?$#_H#Q?^!D7_
M ,57HOP:^&_BCPAXPN;_ %K3U@MGLWB5UN(W^8NA'"DGH#0!TGQ]_P"293_]
M?$7_ *$*\9^!?_)4;+_KC)_*O9OC[_R3*?\ Z^(O_0A7C/P,_P"2H67_ %QD
M_E0!]*^.M#N?$G@K5-(LV1;BYAVQESA<YSR:^>K?X ^-HY@S#3L8(_X^?;_=
MKZ:U;5K+0]*N-3U&;R;2W3?*^"<#Z#D_A7)Z3\7_  5K6J6^FV6JNUU<-LC5
MK:10Q],E<"@#QC2?@IXJT#6+/6=2>PCL=/G2[N'2?<1'&=[8&.3A37I4OQS\
M&:K%)IT,E^DMTIA1GMOE#,,#//3)KO?%W_(E:]_V#KC_ -%M7Q3HZ+_;=A^\
M4_Z3'V/]X>U 'HW_  S[XT:;&=.$9;[WGGIZXQ^E>K'X_>"8G\K?J#;#MW+;
M<''<?-TKU%#F-3C&0.*^2I?@;X^BE<C2H756/S+=Q\@=QE@: /8S^T#X)!P3
MJ61U_P!&'_Q5*_[0'@I'*-_:60<'%L/_ (JOERZMV@O)X975)(Y&5U.>"#@C
MI27*+]JES*HRQ/.?\* /J63X_P#@J-MI_M+H#_Q[#H1D=_>O/?$_PTUSXC:[
M/XL\.R6DFEZCB2$SRF-QQ@@K@XY%>/7:#S^9%'R)U!_NCVKZ&^'7Q7\(>&_
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M7)&?PKR_XV>"/$NN^.5OM*T>ZO+9K9$WPKD C.: /=/#_B72?%%@U[H]XEU
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M3$2R.PQNW XX/H#75?!#6=,\,^*[RZUF^M[2"2U,:RO("N[<#@XSC_ZU=O\
M&GQEX<\1>!Q8:/K%I>7)N4<I%(/E49R23P!T'XB@#SWX'Q[/B?9'>C?NI/NG
M/:OH#XM9_P"%5^(,?\^X_P#0UKP#X(0/%\3K)F,9!BD'RR*QZ>@)KZ*^)&F7
MFL_#S6=/T^!I[N>$+%$I&6.X''/TH ^2/!-];:;XVTB]O)5BMH+E7DD;HH'>
MOJ;_ (7%X%_Z#L7_ 'PW^%?.'_"H?'W_ $+=Q_W\C_\ BJ/^%0^/O^A;N/\
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MY'NK2Z,_%O,<(@^X>R@>E?5'PFUS2+/X;:3;W6IV5O/&K*\4LZHRG<>H)!%
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M:--OOLCC[%<9WC_EDWH?:O=?V;/-EM_$)EWO#N@"[\E<_/G'OR/TKW?R(?\
MGDG_ 'R* /FS]GR":Q\6:C/=Q/;PBTV^9,NQ<EA@9/T-?1O]IV'_ #_6W_?U
M?\:\E_:)9H?!=@(F,>^]^;:<;OE/7UKYN@ED\BY_>-Q&.Y_O+0!]U_VG8?\
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M3:%XXU9-2U"YO89TB$6('4*0/8@UK>"? ^F>!-+GL-,EN)4GF\YWG8$YP!V
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M%Y""VHZIP HPZ=!T_AH J^&O!>C?%OP_;>+?$4+C5)]T4K6\C(K;&*@X['
MX]*]/\+^%M,\(:.NEZ4CI;AV?YW+$D]>:/"GABQ\(>'X-&T]I7MX2S!I2"Q+
M$DYP!ZUM4 %?.O[2+HNNZ%NB5R;:3J2,?,/2NJ^+7Q7UCP)XCL],TRTM)4EM
M!<.\X).2[+@8(_N_K6-X<LK;X]V,U_XD5[2ZTN3R8C8MM5E<9Y# ]Q0!Y/X3
M\?ZQX(6XDT001?:R%E$B;P=O3K_O&O<_@W\2-<\;ZAJ5KK'V=EMXEDC:*/:<
MDX(--_X9U\+; O\ :&J8&3]].O\ WS[5UG@?X9Z-X"N+N?3)[N62Y4(YG<'
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M]/>O3OBE\4]-^(&G6%E;6-W:+;3&5GEVL6)&,8!KS,+;^4W[V7&X9_=#T/\
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M>&_C7X<\3:_:Z/:P7D<]RQ6,N@QG&?Z5T7Q&_P"2=Z[SC_1&R:\0\,_##7_
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M/A.PM_#U]<7,EWID2VLS06Y*%T&T[2<9&1Z4 ?..O:2VD:W=:=>3*MS:L(I
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M50.Y-?5ES<P6=O)<74\<$$:EGDE<*J@=22> *Q1XY\),<+XGT9CZ"^C/_LU
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M\)KW;]I3_D*:%_UPD_\ 0A7A- !7K_[.?_(_WO3_ )!S_P#H:5Y!7K_[.?\
MR4"]Z?\ (.?_ -#2@#T_X^_\DRG_ .OB+_T(5XS\#!GXH60/3R9,_E7LWQ]_
MY)E/_P!?$7_H0KQGX%_\E1LO^N,G\J /H+XM<_"_70.\']17Q_:Q.+A24.,'
M^5?8'Q:Y^%^NCN8  /7YA7R!:P3K< F*1< \E3Z4 -MH91=P_(?]8O\ ,597
M0-8RI_LJ\QU_U#?X58\,PM%XLT>2XC9(4OH#(SKA542#.<]J^WDO;20@)=0L
M3T D!S0!\-_\([K4DVU-*O69FPO[AN23]*^W1J^FJH5M1M P&"/.4?UJ]7PE
M)H^JK=-YNG7@8.=VZ%NN><\4 ?;G]OZ0#@ZG:?\ ?Y:/[?T?&?[3M/\ O\O^
M-?#5Q;3_ &F7$,GWS_ ?6EN+:8W,I6&0KN)X4XH Z'XBNMY\0]<GMV$L3W1V
M.IR&X'0US]S!*6B(C8_ND[>PHNK>9IN(I" B#[I[*!5J[TZ_G,#PV5S(H@0;
MDB8C(7ITH ;_ &5J-U;V[6]C<RJL94M'$6 .YN,CZU]/? BRNK'X=JEW;RP.
MUS(P61"IQZX-6O@TL>F_"W28;L+:SL9G9)?D8_O7P2#@] *]"21)5W1NKJ>Z
MG(H KW6I6-BZI=W<,#.,J)'"DC\:?:WMK?(SVMQ%.JG!,;!@#^%?.'[1EK=S
M>-M->."9X1IR@,J$KN\R3(],XQ^E=1^SKYMEX<U@WF8(WND\KSOE!^4YQF@#
MV:ZO[2Q"FZNH8-YPOF.%R?;-):ZA9WV[[+=0S[?O>6X;'Y5X5^T=')>IX?DM
M%>>)3.':(%E!^3&<<9ZU6_9PM;J'5]:>6"6.)K= "R$ G=0!]!3W$%M'ON)H
MXDSC=(P49_&O+OC@1K'P]>'3&6\E2YC=DMV$C!<XS@=N147[0L<DW@.UCB1G
M<WR':H).-K=OQKSGX @Z?X^G>]!MD>Q=%:8; S;D.,GO@&@#S0:3J-M%,]Q8
MW,*F,X,D149R/455@@E$C'RV^X_;_9-?6?QAQJ'PTU.*SQ<S#8=D/SL!N&3@
M5\M6&DZDMRY;3KL#R)1_J6_YYM[4 4(K:=Y558G9B<  9)-3R:+JD"-)+IUU
M&BCEGA8 ?F*ZKX9:/?\ _"R=!:?3KD1+= N7@;:!@\GBOJCQM UUX#\0P)$9
M9'TVX"1A=Q9O+;&!W.<4 ?$T-O,)E)C/7TIUK$ZWL!9#@2+G\Q5FUTK48[J-
MY+"Z5%.2S0L /TJM;V\ZW,3-#( '!)*'UH ^X+?Q!HYMXB-3M/N#_EJOI5@:
MQIA_YB-I_P!_E_QKX76RNO-'^C3?>_YYFK5[I&I/J%P4T^[96E8J5@8@\]N*
M -7Q7H.KMXMU9ETR\96NI"&6%B""W4&OK/P!;S6OP^T""XC:.5+&(,C#!4[:
MU-#5TT&P5PP86Z AAR/E%7Z "BBB@#YB_:,_Y'BQ_P"O(?\ H1KK_P!FS_D6
MM;_Z_%_] KD/VC/^1XL/^O(?^A&NO_9L_P"1:UO_ *_%_P#0* ,;]I-';5-#
MVJQQ#)G _P!H5X5Y,O\ SS?_ +Y-?>L]E:W3!KBVAF*C ,D8;'YU%_9.F_\
M0/M/^_*_X4 ?!_DR_P#/-_\ ODUZ]^SK&Z^/[TLA4?V<XR1_MI7TE_9.F_\
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M[8$C8&6YQ7D_QXN[JP\?);VD\UM;K:1[8X7*+WS@"@#Z@'ERC(VN/7K7SO\
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M(.X]*EWVV =T.#TY%?"8U740P47]T%SC F;_ !J6YU744NIE6_NE4.P $S
M9^M 'W3]HAQGSH_^^A4G49%?"5UJNH)=2*E_=!0V !,V!^M?9/P^EEG^'GA^
M69WDD:QB+,Y))^7N30!TE%%% 'S%^T9_R/%CS_RY#_T(UY59ZQJ6GQ-%97]S
M;QL=Q6*5E!/3/%?<-_H&CZK,LVH:597<JKM5YX%<@>@)%5?^$-\,?]"[I7_@
M''_A0!\8?\)/KW_09O\ _P "&_QH_P"$GU[_ *#-_P#^!#?XU]G_ /"&^&/^
MA=TK_P  X_\ "C_A#?#'_0NZ5_X!Q_X4 ?&'_"3Z]_T&;_\ \"&_QH_X2?7O
M^@S?_P#@0W^-?9__  AOAC_H7=*_\ X_\*/^$-\,?]"[I7_@''_A0!\576MZ
MK?0&"[U*[GA)!*23,P./8FNY^!?_ "5&R_ZXR?RKZ<_X0WPQ_P!"[I7_ (!Q
M_P"%3V?AO0].N5N++1["VG7@20VR(P_$"@#GOBUD?"_7"."L((([$,.:^0;6
MZN'G56FD*X/&X^E?=UU:P7MM);74*302KM>.1<JP]"*P?^$!\)?]"[IP]Q !
M0!\@^%+FXD\8Z(C3.RMJ$ *EN"/,7BON&L&V\%>&+.YCN;?0=/CGB8/'(L"Y
M4CH1[UO4 (<8.>E?!1O+HRX^T2]?[QK[VK ?P/X5DF:9_#^FM(S;BQMUY/Y4
M 0:!X:T0^'=,=M(LB[6L3,Q@7))4$GIUS7RKXQ\0ZS%XTUJ./5;U(TO941$G
M8*H#$   \ 5]GJJHBHBA548  P *P[KP7X8O;J2YNM!T^6>5MSR/;J2Q/4DX
MH ^-[GQ%K4<VU-6OE&Q3@7#=2H)/7UKZC^&>GV>M_#S2+W5K2"]NWBPTUQ&'
M<@' R3R>*W_^$!\)=_#NG'ZP*:W;2TMK"UCM;2"."WC&U(XU"JH]@* %M[:"
MT@6"WA2*)?NHBX _"J]WH^FW\@DO+"VN' P&EC#$?G5VB@""TL[6PA\FTMXH
M(LYV1(%&?7 KY\_:0GEAUW0A'(Z9MI"=K$?Q#_"OHJL[5- TC6_+_M33;6\\
MO.SSX@VW/7&: /%/V:Y9)1XB,CL^/LX!8Y_OUJ_M#ZG?:?H.D_8KN>W\RY._
MRI"N["G&<5ZQI>AZ5HD<D>EZ?;6:R'<X@C"[C[XI=3T;3-:A6'4["WO(T;<J
MSQA@#ZC- 'Q%)J^I7=I(;B_N9=K*%\R5FQG.<9J"&ZN&AN"T\A*H"N6/!W*,
M_D:^S_\ A ?"7_0NZ=CT\@8/X4?\(#X2S_R+NG#UQ .?KZT ?%\%U<.LVZ:0
MXC)'S=#Q2VM]=I/O6ZF5E5F!#D$$ D'\Z^S_ /A ?"7;P[IP^D %'_" ^$NW
MAW3A]( * /F+X:>(=9E^(VA12:K>/&]R%=&F8@C!R".]?7[*KJ58!E(P01P1
M6+9>#_#>FW:7=EH=A!<1_<DC@4,OT-;= '-:[X:T-=!OV72+(,+=R"(%!''K
MBOC*TNKA[R!&GD*F101N/3(K[Q95=2K ,I&""."*P$\#>%8YUF3P]IJR*P96
M%LO!'?I0!(OAC0?L(']C6&/+[6Z^GTKXNU6XGAUB^BCED1$N'55#'  8X%?=
MF!C&./2L&;P/X5N)WGE\/Z<\DC%G8VZY8GJ3Q0!2\*^&]$?PII3OI%DSM:QE
KBT"DD[1UXKJD1(HUCC1411A548 %$<:11K'&H1%&%51@ 4Z@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
